Updated: Pfizer abandons twice-daily GLP-1 approach due to high discontinuation rates, goes back to PhI with once-a-day dose
Pfizer won’t be moving a twice-daily formulation of its oral GLP-1, danuglipron, into Phase III after the drug triggered high rates of gastrointestinal side effects, despite meeting the primary endpoint of its mid-stage weight loss trial.
The company is now pinning its hopes on a once-daily formulation of danuglipron, which is in Phase I studies with pharmacokinetic data expected in the first half of next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.